What NEXT Life Sciences does

NEXT Life Sciences, Inc. is a clinical-stage private biotechnology company founded in 2021 and headquartered in Los Angeles, California, that is developing non-hormonal male contraceptive products. The company's lead asset, Plan A™, is a long-acting reversible male contraceptive device based on Vasalgel hydrogel technology licensed exclusively worldwide from the Parsemus Foundation (partnership established in 2022). The hydrogel is injected into the vas deferens, where it acts as a flexible filter blocking sperm flow; preclinical studies have shown the contraceptive effect can be reversed by dissolving and flushing the hydrogel. A second product, NLS-133, is a non-hormonal daily or on-demand pill designed to provide 24 hours of protection.

As of early 2026, both products are in Phase II clinical trials. The Plan A delivery system demonstrated 100% device success in early trials conducted in Canada (50 men) and Australia in 2025, and the U.S. patent for the Plan A medical device was granted in December 2025. Commercialization is targeted for approximately 2027 following FDA approval. The company has raised approximately $4 million in total seed funding ($1.55M in June 2023, plus a $2.5M seed extension in January 2024 led by The Family with participation from StartUp Health and Transform VC) and $400,000 in grant funding from the Male Contraceptive Initiative, and is planning a Series A round in 2026.

NEXT Life Sciences has no current revenue, no established pricing, and no commercial distribution channels. Its go-to-market approach upon approval will follow traditional pharmaceutical and medical device pathways (healthcare providers, clinics, and potentially pharmacies), targeting the estimated 17 million+ American men actively seeking new contraceptive options and the broader heterosexual couple segment where shared contraceptive responsibility is desired. The leadership team is anchored by operators from large medical-device and contraceptive companies (former CMO of Endosurgery at Boston Scientific; former CEO of the largest-selling contraceptive company at $1B+ revenue), supplemented by former FDA Chief Counsel Peter Barton Hutt on the advisory board.

Name

NEXT Life Sciences

Legal name

NEXT Life Sciences, Inc.

Website

https://nextlifesciences.org

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

NEXT Life Sciences is a clinical-stage private biotechnology company developing Plan A, a long-acting reversible non-hormonal male contraceptive device using Vasalgel hydrogel, and NLS-133, a non-hormonal on-demand pill, both currently in Phase II trials with commercialization targeted for ~2027.

Ownership category

akta.pro rank

Product category

Male Contraceptive Medical Devices

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industries

Male Reproductive & Sexual Medicine (Andrology) (HLAKAOAD), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Male contraceptive devices
• Non-hormonal contraception
• Reversible fertility control
• Clinical stage biopharmaceuticals
• Contraceptive drug development

Headquarters

HQ city

San Luis Obispo

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Plan A Medical Device: Long-acting reversible male contraceptive device commercialized as a medical product. The company holds exclusive worldwide license for Vasalgel technology and plans market entry around 2027 following FDA approval.
2. NLS-133 Pharmaceutical Product: Non-hormonal daily or on-demand pill for male contraception. Currently in Phase II clinical trials evaluating effectiveness through semen level measurements.

Go-to-market motion2 records

Marketing channels4 records

Core offering

NEXT Life Sciences is developing two non-hormonal male contraceptive products: Plan A™, a long-acting reversible device that injects Vasalgel hydrogel into the vas deferens to block sperm flow and can be reversed by dissolving the hydrogel, and NLS-133, a non-hormonal on-demand or daily pill providing 24 hours of protection. Both candidates are in Phase II clinical trials, with the company holding an exclusive worldwide license for Vasalgel technology and a granted U.S. patent for the Plan A device.

Product overview

NEXT Life Sciences is developing two distinct male contraceptive products: Plan A™ is a long-acting, non-hormonal, reversible device that uses Vasalgel hydrogel injected into the vas deferens to block sperm flow, with reversibility achieved by dissolving and flushing the hydrogel; NLS-133 is a separate non-hormonal pill designed for 24-hour on-demand or daily use. Both products are non-hormonal contraceptives targeting the substantial market gap where over 17 million American men seek new contraceptive options. The company holds an exclusive worldwide license for the Vasalgel technology and has received patent protection for the Plan A device.

Differentiator

Problem solved

Functional benefit

Brands

• Plan A: Long-acting, non-hormonal, reversible male contraceptive device using Vasalgel hydrogel technology, injected into the vas deferens to block sperm flow.
• NLS-133

Products and services

• Plan A™ A long-acting, non-hormonal, reversible male contraceptive device that injects Vasalgel hydrogel into the vas deferens where it acts as a flexible filter blocking sperm flow. The contraceptive effect can be reversed on-demand by dissolving and flushing the hydrogel. Targeted at adult men and couples seeking shared contraceptive responsibility, with commercialization planned around 2027 following FDA approval.
• NLS-133 A non-hormonal male contraceptive pill designed for on-demand or daily use, providing 24 hours of protection. Currently in Phase II clinical trials evaluating participants' semen levels to demonstrate effectiveness. Targeted at individual men and couples seeking a non-hormonal, short-acting contraceptive option.

Quantifiable outcome

• 100% delivery device success in clinical trials
• +3 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered minor and core.

• Peter Barton HuttminorOthers · 29 August 2025Former Chief Counsel at the U.S. Food & Drug Administration joined NEXT Life Sciences advisory board to help advance Plan A toward potential FDA approval. His appointment is intended to help navigate the regulatory pathway.
• Parsemus FoundationcoreStrategic or Co-development Partner · 1 January 2022Parsemus Foundation initially developed Vasalgel technology and partnered with NEXT Life Sciences in 2022 to bring the product to market as an affordable and accessible birth control option for men. NEXT Life Sciences acquired exclusive worldwide license for the Vasalgel technology.
• Cornell UniversityminorStrategic or Co-development PartnerResearch collaboration for broader male contraceptive development, though this appears related to different research (JQ1 molecule study) rather than the company's primary products.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Contraline: Contraline is developing ADAM, a long-acting reversible hydrogel-based male contraceptive injected into the vas deferens — the most direct mechanistic and clinical-stage competitor to NEXT Life Sciences' Plan A. Both companies target the same first-in-class non-hormonal reversible male contraceptive category.

Broad incumbents

• AbbVie: AbbVie operates a broad reproductive health portfolio (Lo Loestrin, Lupron, Orilissa) and has the commercial footprint and balance sheet to enter the male contraceptive category either through acquisition of a company like NLS or through internal development of competing assets.
• Bayer: Bayer is a major incumbent in reproductive health with blockbuster contraceptive franchises (Mirena IUD, Yaz, etc.) and a deep women's health commercial infrastructure that could be leveraged to scale a male contraceptive. It is a broad comparator for go-to-market scale and a likely strategic acquirer.
• TherapeuticsMD: TherapeuticsMD is a women's health pharmaceutical company with FDA-approved contraceptive and hormone therapy products. It represents a comparable commercial-stage reproductive health company and a potential strategic partner or acquirer for NLS at scale.
• Organon: Organon is a global women's health-focused pharmaceutical company spun out of Merck with a broad contraceptive portfolio (e.g., Nexplanon, NuvaRing). While focused on female contraception today, Organon is a logical strategic acquirer or competitor if it expands into the male contraceptive market.
• Dare Bioscience: Dare Bioscience is a clinical-stage biopharmaceutical company focused on women's health, including contraceptive product candidates. It is a relevant comparator as a similarly-sized, publicly traded reproductive health developer pursuing novel contraceptive mechanisms.

Emerging players

• YourChoice Therapeutics: YourChoice Therapeutics is a venture-backed startup developing non-hormonal contraceptives for men and women, including a vas deferens-targeted approach. It overlaps with NEXT's male contraceptive focus and represents another emerging competitor in the non-hormonal reversible category.
• Eppin Pharma: Eppin Pharma is developing a non-hormonal oral male contraceptive pill targeting the Eppin protein on sperm — directly comparable to NLS-133 as a competing on-demand non-hormonal male pill. It is one of the few companies pursuing male contraception through a small-molecule oral route.

Others

• Population Council: The Population Council is a non-profit research organization that has historically driven much of the male contraceptive pipeline, including earlier work on Vasalgel-adjacent technologies. It functions as an enabling research partner and indirect ecosystem participant rather than a commercial competitor.
• Hims & Hers Health: Hims & Hers is a consumer telehealth platform with a growing men's health category (including treatments historically limited to in-person visits). It is an adjacent — rather than direct — comparator for NLS's eventual consumer-facing male contraceptive distribution model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/nextlifescience
• Facebookfacebook.com/planaformen

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NEXT Life Sciences